Read by QxMD icon Read

Acei and colorectal cancer

Gregory Charak, Benjamin A Kuritzkes, Ahmed Al-Mazrou, Kunal Suradkar, Neda Valizadeh, Steven A Lee-Kong, Daniel L Feingold, Emmanouil P Pappou
PURPOSE: Diverting ileostomies help prevent major complications related to anastomoses after colorectal resection but can cause metabolic derangement and hypovolemia, leading to readmission. This paper aims to determine whether angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use increased the risk of readmission, or readmission specifically for dehydration after new ileostomy creation. METHODS: Retrospective analysis of patients undergoing diverting ileostomy at a tertiary-care hospital, 2009-2015...
March 2018: International Journal of Colorectal Disease
Ishveen Chopra, Nilanjana Dwibedi, Malcolm D Mattes, Xi Tan, Patricia Findley, Usha Sambamoorthi
Background: Incident cancer diagnosis may increase the risk of coronary artery disease (CAD)-related hospitalizations, especially in older individuals. Adherence to statins and/or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/β-blockers reduces CAD-related hospitalizations. This study examined the relationship between medication adherence and CAD-related hospitalizations immediately following cancer diagnosis. Patients and Methods: A retrospective observational longitudinal study was conducted using SEER-Medicare data...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
Trinidad Dierssen-Sotos, Inés Gómez-Acebo, Camilo Palazuelos, Francisco Rodriguez-Moranta, Beatriz Pérez-Gómez, José Pedro Fernández Vazquez, Pilar Amiano, Aurelio Barricarte, Benito Mirón-Pozo, Adonina Tardon, Rocío Capelo, Rosana Peiro Pérez, José María Huerta, Montserrat Andreu, Mª Ángeles Sierra, Carmen Castañón López, Irune Ruiz, Concepción Moreno-Iribas, Rocío Olmedo-Requena, Gemma Castaño-Vinyals, Nuria Aragonés, Manolis Kogevinas, Marina Pollán, Javier Llorca
The potential protective effect of renin-angiotensin system (RAS) inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against colorectal cancer (CRC). To evaluate this association, we conducted a case-control study with 2165 cases of colorectal cancer, diagnosed between 2007 and 2012, and 3912 population controls frequency matched (by age, sex and region) from the Spanish multicenter case-control study MCC-Spain. We found a significant protective effect of the angiotensin-converting enzyme Inhibitors (ACEIs) against CRC, limited to the under-65years group (OR=0...
January 26, 2017: Preventive Medicine
Taejong Song, Chel Hun Choi, Mi Kyoung Kim, Mi-La Kim, Bo Seong Yun, Seok Ju Seong
To assess the current evidence on the potential benefit of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on cancer recurrence and survival, we comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors screened out duplicates and independently reviewed the eligibility of each study. We included comparative studies comparing the use and nonuse of ACEIs or ARBs in cancer patients. Primary outcomes were disease-free survival (DFS) and overall survival...
January 2017: European Journal of Cancer Prevention
Yi-Ning Dai, Jing-Hua Wang, Jin-Zhou Zhu, Jie-Qiong Lin, Chao-Hui Yu, You-Ming Li
PURPOSE: We aim to investigate the association between angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) therapy and colorectal cancer (CRC) by conducting a systematic review with meta-analysis. METHODS: Literature was searched on PubMed, Scopus, and the Cochrane library to identify relevant studies evaluating ACEIs/ARBs therapy and risk of CRC incidence or survival of CRC patients. Pooled risk ratio (RR) with 95% confidence intervals was calculated for the association between ACEIs/ARBs and CRC risk and mortality...
September 2015: Cancer Causes & Control: CCC
Ileana Sonia Fernández Hernández, Sergio Santana Porbén
Every medical surgical action implies costs. Costs of medical provisions should be translated into tangible, and thus, measurable, benefits for the health status of the patient. Nutritional support therapies might increase the costs of medical provisions, but it is expected their implementation to result in lower morbidity and mortality rates as well as shortening of hospital stay, all of them leading to important savings. It is then required the assimilation of tools for costs analysis for a better management of nutritional support therapies...
June 1, 2015: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
Chris R Cardwell, Úna C Mc Menamin, Blánaid M Hicks, Carmel Hughes, Marie M Cantwell, Liam J Murray
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are commonly prescribed to the growing number of cancer patients (more than two million in the UK alone) often to treat hypertension. However, increased fatal cancer in ARB users in a randomized trial and increased breast cancer recurrence rates in ACEI users in a recent observational study have raised concerns about their safety in cancer patients. We investigated whether ACEI or ARB use after breast, colorectal or prostate cancer diagnosis was associated with increased risk of cancer-specific mortality...
February 13, 2014: BMC Medicine
Diana R Engineer, Basil O Burney, Teresa G Hayes, Jose M Garcia
BACKGROUND: Advanced colon cancer is associated with weight loss and decreased survival. Studies suggest that angiotensin and β-adrenergic blockade decrease colon cancer progression and ameliorate weight loss. This study aims to determine whether exposure to β-adrenoceptor blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) is associated with decreased mortality, tumor progression, number of hospitalizations, or weight loss in colorectal cancer...
2013: Translational Oncology
Signy Holmes, E Jane Griffith, Grace Musto, Gerald Y Minuk
BACKGROUND: The association between antihypertensive medications and survival in cancer patients remains unclear. OBJECTIVES: To explore the association between classes of antihypertensive drugs and survival in cancer patients. METHODS: Provincial Cancer Registry data was linked with a Provincial Drug Program Information Network (DPIN) for patients with lung (n=4241), colorectal (n=3967), breast (n=4019) or prostate (n=3355) cancer between the years of 2004 and 2008...
December 2013: Cancer Epidemiology
Úna C Mc Menamin, Liam J Murray, Marie M Cantwell, Carmel M Hughes
OBJECTIVE: To investigate the association between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) and disease progression and survival in cancer patients. METHODS: Using terms for cancer and ACEIs/ARBs, MEDLINE, EMBASE and Web of Science were systematically searched for observational/interventional studies that used clinically relevant outcomes for cancer progression and survival. RESULTS: Ten studies met the inclusion criteria...
February 2012: Cancer Causes & Control: CCC
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"